The study, published Wednesday in the New England Journal of Medicine, included 800 adults with a severe form of liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH.

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH ...